Cleveland-based AxioMed Spine has garnered $3.6 million in capital funding for development of its degenerative spine products, according to Med City News. It has collected more than $34 million in private financing since its founding in 2001.
The company is currently in the process of getting its Freedom Lumbar artificial disc replacement launched in the U.S. The product, which mimics the natural motion of the spine, is in limited use in Germany, Switzerland and the United Kingdom.
AxioMed hopes to receive FDA clearance by the end of 2014.
More Articles on Devices:
GE Capital Invests $21.5M for Amedica Spine Device Development
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in December
TranS1 Pays $6M to Settle Federal Investigation
The company is currently in the process of getting its Freedom Lumbar artificial disc replacement launched in the U.S. The product, which mimics the natural motion of the spine, is in limited use in Germany, Switzerland and the United Kingdom.
AxioMed hopes to receive FDA clearance by the end of 2014.
More Articles on Devices:
GE Capital Invests $21.5M for Amedica Spine Device Development
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in December
TranS1 Pays $6M to Settle Federal Investigation